The mechanism of axitinib as a multi-target tyrosine kinase inhibitor

Axitinib is an oral small molecule targeted anticancer drug mainly used to treat advanced renal cell carcinoma (RCC). The core of its mechanism of action is to block the angiogenesis pathway of tumor tissue by potently inhibiting multiple vascular endothelial growth factor receptor (VEGFR) family members. As a multi-target tyrosine kinase inhibitor, axitinib not only targets VEGFR-1, VEGFR-2 and VEGFR-3, but also inhibits the PDGFR and c-Kit signaling pathways to a certain extent, limiting the tumor's blood supply, nutrient acquisition and spreading ability from multiple angles.

Tyrosine kinase is a key enzyme in a variety of cell signaling processes, especially playing a key role in abnormal proliferation, migration and angiogenesis of tumor cells. By inhibiting the phosphorylation activity of these kinases, axitinib cuts off the "communication" between tumor cells and their microenvironment, forcing tumors into a hypoxic state and limiting the formation of new blood vessels, significantly slowing down tumor growth. Its high selectivity acts on blood vessel-related receptors and reduces the impact on normal tissues. Therefore, it is considered to be one of the more precise anti-angiogenic therapeutic drugs in clinical practice.

In addition, the molecular structure design of axitinib makes it have good oral absorption and bioavailability, and allows individualized dose adjustment to adapt to the tolerance levels of different patients. In current treatment strategies, it is often used as a back-line treatment option after first-line immune or other targeted therapies fail, and can also be used in combination with other immune checkpoint inhibitors to improve efficacy. For VEGF pathway-dependent tumors, axitinib has a clear mechanism and powerful effect, making it an important representative in the era of precision medicine.

Reference materials:https://en.wikipedia.org/wiki/Axitinib